Can Asiminib be combined with Ponatinib?

Ponatinib (Ponatinib) is a tyrosine kinase inhibitor (TKI) targetingBCR-ABL1, which has been successfully used in patients with BCR-ABL1 T315I+ chronic myelogenous leukemia (CML). However, BCR-ABL1 complex mutations may arise during treatment in these patients and may lead to drug resistance. Asciminib is a new drug that targets most BCR-ABL1 mutant forms, including BCR-ABL1T315I, but is ineffective against most subclones carrying BCR-ABL1T315I+ compound mutations.

Studies have shown that aximinib and ponatinib synergistically induce growth arrest and apoptosis in patient-derived CML cell lines and mouse Ba/F3 cells carrying BCR-ABL1 T315I or T315I-including compound mutations. Aceminib andponatinib also had a synergistic effect on CRKL phosphorylation inBCR-ABL1-transformed cells. The growth-inhibitory effect of the aximini + ponatinib drug combination was further enhanced by hydroxyurea (HU), a drug recently described to inhibit the proliferation of BCR-ABL1 T315I+ CML cells. Synergistic drug effects were also observed in patient-derived chronic myelogenous leukemia cells.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in the medical insurance. The original drug of Asiminib sold overseas is very expensive. The price of 20mg*60 oral tablets is about more than 20,000 US dollars, which is about 150,000 yuan in RMB. There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.